Aleena Banerji

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11687225/publications.pdf

Version: 2024-02-01

149 papers	7,210 citations	46918 47 h-index	66788 78 g-index
150 all docs	150 docs citations	150 times ranked	4793 citing authors

#	Article	IF	Citations
1	Urticaria and/or angioedema secondary to <scp>mRNA COVID</scp>â€19 vaccines: Updates from a United States case registry. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 283-286.	2.7	12
2	Longâ€term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 979-990.	2.7	33
3	COVIDâ€19 vaccines tolerated in patients with paclitaxel and docetaxel allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1048-1051.	2.7	8
4	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	2.7	153
5	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Advances, 2022, , .	2.5	14
6	Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine. Journal of Infectious Diseases, 2022, 226, 1231-1236.	1.9	1
7	Case 8-2022: A 54-Year-Old Woman with Episodes of Swelling. New England Journal of Medicine, 2022, 386, 1071-1079.	13.9	2
8	The international WAO/EAACI guideline for the management of hereditary angioedema â€" The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	1.6	37
9	Rapid progress in our understanding of COVID-19 vaccine allergy: AÂcause for optimism, not hesitancy. Journal of Allergy and Clinical Immunology, 2022, 150, 12-16.	1.5	11
10	Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement. World Allergy Organization Journal, 2022, 15, 100640.	1.6	18
11	We should not abandon the Brighton Collaboration criteria for vaccine-associated anaphylaxis. Annals of Allergy, Asthma and Immunology, 2022, 129, 17-19.	0.5	6
12	Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: AÂrandomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology, 2021, 148, 164-172.e9.	1.5	75
13	Current medical management of hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2021, 126, 264-272.	0.5	26
14	US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 132-150.e3.	2.0	158
15	Impact of lanadelumab on healthâ€related quality of life in patients with hereditary angioedema in the HELP study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1188-1198.	2.7	28
16	Perioperative Allergic Reactions: Allergy Assessment and Subsequent Anesthesia. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1980-1991.	2.0	14
17	Penicillin Allergy Assessment in Pregnancy: Safety and Impact on Antibiotic Use. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1338-1346.	2.0	37
18	Optimal Management of Hereditary Angioedema: Shared Decision-Making. Journal of Asthma and Allergy, 2021, Volume 14, 119-125.	1.5	17

#	Article	IF	Citations
19	Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases, 2021, 16, 86.	1.2	10
20	Reply to â€œPenilloate and penicilloate concentrations in practical guidance recommendationsâ€• Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1419-1420.	2.0	0
21	The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2556-2561.	2.0	4
22	mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1423-1437.	2.0	351
23	Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. New England Journal of Medicine, 2021, 384, 1273-1277.	13.9	226
24	Immediate reaction to ibrutinib amenable to oral desensitization. Journal of Oncology Pharmacy Practice, 2021, 27, 1802-1805.	0.5	0
25	Reply to â€œPEG skin testing for COVID-19 allergyâ€• Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1765-1766.	2.0	3
26	Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2021, 325, 1562.	3.8	194
27	Consensus on treatment goals in hereditary angioedema: AÂglobal Delphi initiative. Journal of Allergy and Clinical Immunology, 2021, 148, 1526-1532.	1.5	27
28	Caregiversâ€™ role in managing hereditary angioedema and perceptions of treatment-related burden. Allergy and Asthma Proceedings, 2021, 42, S11-S16.	1.0	11
29	Insights into the treatment burden of hereditary angioedema in the evolving treatment landscape. Allergy and Asthma Proceedings, 2021, 42, S1-S3.	1.0	5
30	Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. Allergy and Asthma Proceedings, 2021, 42, S17-S25.	1.0	14
31	Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy and Asthma Proceedings, 2021, 42, S4-S10.	1.0	25
32	Reply to â€œHow important is the second dose of the COVID-19 mRNA vaccine?â€• Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2537-2539.	2.0	0
33	Drug desensitization in the coronavirus disease 2019 pandemic era. Annals of Allergy, Asthma and Immunology, 2021, 126, 739-741.	0.5	0
34	COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2135-2138.	2.0	37
35	Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. Clinical and Experimental Allergy, 2021, 51, 1391-1395.	1.4	2
36	Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine, 2021, 181, 1530.	2.6	84

#	Article	IF	Citations
37	First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3308-3320.e3.	2.0	109
38	Reply to â€œIsosulfan blue-induced perioperative systemic allergic reactionsâ€. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3845.	2.0	0
39	Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination. JAMA Network Open, 2021, 4, e2131034.	2.8	18
40	Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection. Infection Control and Hospital Epidemiology, 2021, , 1-8.	1.0	3
41	Natural Language Processing Combined with ICD-9-CM Codes as a Novel Method to Study the Epidemiology of Allergic Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1032-1038.e1.	2.0	20
42	Platin risk stratification algorithm with modified intradermal skin test protocol. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1139-1141.	2.0	5
43	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S3-S15.	2.0	50
44	Controversies in Allergy: Chemotherapy Reactions, Desensitize, or Delabel?. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2907-2915.e1.	2.0	27
45	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	2.0	107
46	Implementation and assessment of an anaphylaxis simulation curriculum for Boston-area allergy and immunology trainees. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3616-3618.	2.0	4
47	Patient Characteristics and Concerns about Drug Allergy: A Report from the United States Drug Allergy Registry. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2958-2967.	2.0	19
48	Hereditary angioedema: Special considerations in women. Allergy and Asthma Proceedings, 2020, 41, S47-S50.	1.0	21
49	Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2879-2887.	2.7	25
50	Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3162-3169.e5.	2.0	4
51	Preoperative penicillin allergy testing in patients undergoing cardiac surgery. Annals of Allergy, Asthma and Immunology, 2020, 124, 583-588.	0.5	25
52	Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1875-1880.e3.	2.0	10
53	Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	2.7	29
54	Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Annals of Allergy, Asthma and Immunology, 2020, 124, 600-607.	0.5	64

#	Article	IF	Citations
55	Risk-based pathway for outpatient penicillin allergy evaluations. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2411-2414.e1.	2.0	43
56	Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018. Journal of Allergy and Clinical Immunology, 2019, 144, 381-392.	1.5	19
57	Electronic Consultations in Allergy/Immunology. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2594-2602.	2.0	32
58	Sex differences in academic rank in allergy/immunology. Journal of Allergy and Clinical Immunology, 2019, 144, 1697-1702.e1.	1.5	17
59	New and evolving therapies for hereditary angioedema. Allergy and Asthma Proceedings, 2019, 40, 7-13.	1.0	12
60	Cephalosporin Allergy: Current Understanding and Future Challenges. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2105-2114.	2.0	69
61	Outpatient oxaliplatin desensitizations. Annals of Allergy, Asthma and Immunology, 2019, 123, 605-607.e1.	0.5	6
62	Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1679-1683.e7.	2.0	19
63	Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2035-2038.	2.0	9
64	Platin chemotherapy hypersensitivity reactions: Expanding the scope of practice and improving care. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1691-1695.e2.	2.0	9
65	Allergic Reactions Captured by Voluntary Reporting. Journal of Patient Safety, 2019, Publish Ahead of Print, e1595-e1604.	0.7	8
66	Controversies in Drug Allergy: Drug Allergy Pathways. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 46-60.e4.	2.0	52
67	Identification of Inpatient Allergic Drug Reactions Using ICD-9-CM Codes. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 259-264.e1.	2.0	24
68	Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. BioDrugs, 2019, 33, 33-43.	2.2	15
69	Cutaneous Manifestations of Reactions to Biologics. Current Allergy and Asthma Reports, 2018, 18, 12.	2.4	6
70	Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1733-1741.e3.	2.0	67
71	The Cost of Penicillin Allergy Evaluation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1019-1027.e2.	2.0	87
72	Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1266-1273.e2.	2.0	28

#	Article	IF	Citations
73	Hereditary angioedema from the patient's perspective: A follow-up patient survey. Allergy and Asthma Proceedings, 2018, 39, 212-223.	1.0	40
74	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. JAMA - Journal of the American Medical Association, 2018, 320, 2108.	3.8	174
75	Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. Orphanet Journal of Rare Diseases, 2018, 13, 180.	1.2	12
76	Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. New England Journal of Medicine, 2017, 376, 717-728.	13.9	138
77	Immediate Hypersensitivity Reaction to Chemotherapeutic Agents. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 593-599.	2.0	41
78	Acquired C1 Inhibitor Deficiency. Immunology and Allergy Clinics of North America, 2017, 37, 497-511.	0.7	26
79	Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 744-749.	2.0	80
80	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine, 2017, 376, 1131-1140.	13.9	169
81	Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. Journal of Allergy and Clinical Immunology, 2017, 140, 242-248.e2.	1.5	73
82	Platinum Chemotherapy Hypersensitivity. Immunology and Allergy Clinics of North America, 2017, 37, 663-677.	0.7	38
83	Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Annals of Allergy, Asthma and Immunology, 2017, 119, 59-64.	0.5	28
84	Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 442-447.e1.	2.0	8
85	Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 107-113.e1.	2.0	56
86	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 177-178.	2.0	14
87	Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 128-134.e4.	2.0	18
88	An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clinical and Translational Allergy, 2017, 7, 36.	1.4	28
89	Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey. Allergy and Rhinology, 2016, 7, ar.2016.7.0165.	0.7	17
90	Antibiotics Are the Most Commonly Identified Cause of Perioperative Hypersensitivity Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 697-704.	2.0	47

#	Article	IF	Citations
91	Allergen immunotherapy: No evidence of infectious risk. Journal of Allergy and Clinical Immunology, 2016, 137, 1887-1888.	1.5	13
92	Immune-mediated reactions to vancomycin. Annals of Allergy, Asthma and Immunology, 2016, 116, 544-553.	0.5	65
93	Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 740-746.	2.0	29
94	Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. Pediatrics, 2016, 138, .	1.0	46
95	Managing the Female Patient with Hereditary Angioedema. Women's Health, 2016, 12, 351-361.	0.7	29
96	Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management. Current Allergy and Asthma Reports, 2016, 16, 17.	2.4	23
97	Immediate and Delayed Hypersensitivity Reactions to Corticosteroids: Evaluation and Management. Current Allergy and Asthma Reports, 2016, 16, 18.	2.4	23
98	Utility of ICD-9-CM Codes for Identification of Allergic Drug Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 114-119.e1.	2.0	24
99	Hereditary angioedema: Special consideration in children, women of childbearing age, and the elderly. Allergy and Asthma Proceedings, 2015, 36, 425-432.	1.0	11
100	Before and after, the impact of available on-demand treatment for HAE. Allergy and Asthma Proceedings, 2015, 36, 145-150.	1.0	42
101	Current state of hereditary angioedema management: A patient survey. Allergy and Asthma Proceedings, 2015, 36, 213-217.	1.0	76
102	Current characteristics associated with hereditary angioedema attacks and treatment: The home infusion based patient experience. Allergy and Asthma Proceedings, 2015, 36, 151-159.	1.0	8
103	Ceftaroline Desensitization Procedure in a Pregnant Patient With Multiple Drug Allergies. Open Forum Infectious Diseases, 2015, 2, ofv027.	0.4	4
104	Current Medical Management of Hereditary Angioedema: Follow-up Survey of US Physicians. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 220-227.	2.0	18
105	Comprehensive Allergy Evaluation Is Useful in the Subsequent Care of Patients with Drug Hypersensitivity Reactions During Anesthesia. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 94-100.	2.0	51
106	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. Journal of Allergy and Clinical Immunology, 2015, 136, 262-271.e2.	1.5	51
107	Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Annals of Allergy, Asthma and Immunology, 2015, 115, 294-300.e2.	0.5	147
108	Skin Testing in the Evaluation and Management ofÂCarboplatin-Related Hypersensitivity Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 856-862.	2.0	35

#	Article	IF	Citations
109	Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Annals of Allergy, Asthma and Immunology, 2015, 115, 422-428.	0.5	40
110	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 826-827.	2.0	2
111	A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 984-985.	2.0	13
112	Tolerability of Cefazolin after Immune-Mediated Hypersensitivity Reactions to Nafcillin in the Outpatient Setting. Antimicrobial Agents and Chemotherapy, 2014, 58, 3137-3143.	1.4	23
113	Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 40-45.	2.0	65
114	Safety and Outcomes of Test Doses for the Evaluation of Adverse Drug Reactions: A 5-Year Retrospective Review. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 768-774.	2.0	48
115	A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department. Academic Emergency Medicine, 2014, 21, 469-484.	0.8	105
116	Retrospective Study of Drug-induced Anaphylaxis Treated in the Emergency Department or Hospital: Patient Characteristics, Management, and 1-Year Follow-up. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 46-51.	2.0	65
117	Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks. Annals of Allergy, Asthma and Immunology, 2014, 112, 471-472.	0.5	7
118	Effect of a Drug Allergy Educational Program and Antibiotic Prescribing Guideline on Inpatient Clinical Providersâ€™ Antibiotic Prescribing Knowledge. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 407-413.	2.0	81
119	Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 428-433.	2.0	63
120	Evaluation and management of a patient with multiple drug allergies. Allergy and Asthma Proceedings, 2014, 35, 197-203.	1.0	13
121	The burden of illness in patients with hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2013, 111, 329-336.	0.5	86
122	Evaluation and management of hypersensitivity to proton pump inhibitors. Annals of Allergy, Asthma and Immunology, 2013, 111, 452-457.	0.5	30
123	US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 458-467.	2.0	131
124	An update on self-injectable epinephrine. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 432-437.	1.1	8
125	Favorable trends in the frequency of U.S. emergency department visits for food allergy, 2001â€2009. Allergy and Asthma Proceedings, 2013, 34, 439-445.	1.0	16
126	Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy and Asthma Proceedings, 2012, 33, 145-156.	1.0	142

#	Article	IF	Citations
127	A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 2012, 129, 443-447.	1.5	75
128	Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. Journal of Allergy and Clinical Immunology, 2012, 130, 1216-1218.	1.5	17
129	Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease.. Journal of Clinical Oncology, 2012, 30, e18520-e18520.	0.8	1
130	Predictors of hospital admission for food-related allergic reactions that present to the emergency department. Annals of Allergy, Asthma and Immunology, 2011, 106, 42-48.	0.5	23
131	Frequency of US emergency department visits for food-related acute allergic reactions. Journal of Allergy and Clinical Immunology, 2011, 127, 682-683.	1.5	86
132	Hereditary angioedema: Classification, pathogenesis, and diagnosis. Allergy and Asthma Proceedings, 2011, 32, 403-407.	1.0	28
133	Multicenter Study of Repeat Epinephrine Treatments for Food-Related Anaphylaxis. Pediatrics, 2010, 125, e711-e718.	1.0	112
134	Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. New England Journal of Medicine, 2010, 363, 532-541.	13.9	477
135	Multiple epinephrine doses for stinging insect hypersensitivity reactions treated in the emergency department. Annals of Allergy, Asthma and Immunology, 2010, 105, 85-93.	0.5	39
136	Trends in pediatric emergency department visits for food-induced anaphylaxis. Journal of Allergy and Clinical Immunology, 2010, 126, 385-388.	1.5	113
137	Repeat epinephrine treatments for food-related allergic reactions that present to the emergency department. Allergy and Asthma Proceedings, 2010, 31, 308-316.	1.0	52
138	Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. Journal of Allergy and Clinical Immunology, 2009, 123, 1262-1267.e1.	1.5	101
139	The spectrum of chronic angioedema. Allergy and Asthma Proceedings, 2009, 30, 11-16.	1.0	39
140	Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Annals of Allergy, Asthma and Immunology, 2008, 100, 327-332.	0.5	194
141	Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2008, 100, S19-S22.	0.5	61
142	Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult service. Allergy and Asthma Proceedings, 2008, 29, 88-92.	1.0	26
143	Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: A literature review. Allergy and Asthma Proceedings, 2007, 28, 418-426.	1.0	44
144	Multiple Chemokine Receptors, Including CCR6 and CXCR3, Regulate Antigen-Induced T Cell Homing to the Human Asthmatic Airway. Journal of Immunology, 2007, 179, 1901-1912.	0.4	102

#	Article	IF	Citations
145	Chronic Rhinosinusitis Patients with Polyps or Polypoid Mucosa have a Greater Burden of Illness. American Journal of Rhinology & Allergy, 2007, 21, 19-26.	2.3	105
146	Food-induced anaphylaxis and repeated epinephrine treatments. Annals of Allergy, Asthma and Immunology, 2007, 99, 429-432.	0.5	67
147	Cytokine-Associated Angioedema Syndromes Including Episodic Angioedema with Eosinophilia (Gleich's) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	32
148	Prospective Multicenter Study of Acute Asthma in Younger Versus Older Adults Presenting to the Emergency Department. Journal of the American Geriatrics Society, 2006, 54, 48-55.	1.3	51
149	Pathogenic T-Cell Recruitment into the Airway in Human Disease. Annals of the New York Academy of Sciences, 2005, 1062, 220-241.	1.8	19